GlassScriptPhysician profile
Mark Edward Schrand
NPI 1427056811
$2,044.02
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $971 · 2020: $271 · 2021: $185 · 2022: $385 · 2023: $231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $231.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $353.70 | 2019-2023 | Qulipta, Vraylar |
| Lilly USA, LLC | $266.53 | 2019-2023 | Mounjaro, Jardiance |
| Novo Nordisk INC | $210.79 | 2019-2023 | Wegovy, Saxenda |
| Boehringer Ingelheim Pharmaceuticals, INC. | $167.50 | 2019-2022 | |
| Pfizer INC. | $166.50 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $159.08 | 2019-2022 | |
| Amarin Pharma, INC. | $147.99 | 2019-2021 | |
| Amgen INC. | $127.96 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.16 | 2019-2023 | Xifaxan |
| Janssen Pharmaceuticals, INC | $53.55 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $41.60 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $32.30 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $29.96 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $27.12 | 2021 | |
| Dexcom, INC. | $22.23 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $21.92 | 2022 | |
| Novartis Pharmaceuticals Corporation | $20.06 | 2019 | |
| Glaxosmithkline, LLC. | $19.04 | 2019 | |
| Gilead Sciences, INC. | $18.78 | 2020 | |
| Ironshore Pharmaceuticals INC. | $16.25 | 2019 | |
| Astellas Pharma US INC | $16.16 | 2019 | |
| Allergan, INC. | $13.38 | 2020 | |
| Sanofi Pasteur INC. | $12.65 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.56 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $11.43 | 2020 | |
| Shire North American Group INC | $10.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Schrand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.